DMTN

Across TCGA pan-cancer cohorts, DMTN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DMTN data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DMTN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DMTN expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where DMTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.881	0.567	.001	24	view →
COAD	DFS	Median	III,IV	1.000	0.835	.032	12	view →
LUAD	DFS	Median	III,IV	0.285	0.722	.017	6	view →
PDAC	OS	Median	II,III,IV	0.703	0.950	.001	5	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	1	view →
LSCC	DFS	Median	All	0.899	0.514	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DMTN–CCRCC (DFS)

Open the CCRCC breakdown →